DAEDALUS is a Horizon Europe-funded research project aiming to transform the treatment of colorectal diseases (CRDs) through a new generation of minimally invasive, regenerative solutions. These diseases, such as ulcerative colitis and familial adenomatous polyposis, currently require invasive surgery with serious long-term consequences.

DAEDALUS proposes an alternative: the replacement of damaged tissues using injectable 4D biomaterials, enriched with therapeutic molecules and patient-derived cells. The goal is to restore tissue function while reducing complications and improving quality of life.

What makes DAEDALUS unique?

  • 4D biomaterials that adapt their shape after injection to match tissue architecture
  • Controlled drug delivery: biomolecules are released over time to support healing

  • Smart nanoparticles and engineered grids to guide cell growth and structure

  • Endoscopic toolhead for in situ application with existing clinical devices

This combination enables targeted, patient-specific therapies with reduced surgical burden.

Mission

Our mission is to provide a viable, scalable alternative to radical colorectal surgery that can benefit patients across Europe and beyond. DAEDALUS sets a new direction in how we approach chronic gastrointestinal diseases with science, precision, and care for our patients.

Scientific foundations

The project’s approach ensures biocompatibility, functionality, and future clinical usability from the earliest design stages.

DAEDALUS merges expertise in:

Materials Science

Development of biopolymers, composites, and microengineered structures for advanced 4D biomaterials targeting mucosal and submucosal intestinal treatment.

Medical and surgical engineering

Design and development of medical and surgical engineering solutions to integrate with 4D biomaterials for mucosal and submucosal regeneration in intestinal diseases.

Tissue regeneration and immunology

Study of regenerative mechanisms and immune interactions to optimize 4D biomaterials for healing of intestinal mucosa and submucosa.

In situ printing and nanotechnology

Application of in situ printing and nanotechnology for the precise delivery and activation of 4D biomaterials in mucosal and submucosal intestinal tissues.